Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048852 | 1.00 | GPR119 (0.42) | GPR119NSD2SLC2A1EHMT2PDE4A | |
| SCHEMBL16760543 | 0.88 | ABL1 (0.38) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5049586 | 0.85 | F2RL3 (0.39) | GPR119NSD2EHMT2 | |
| SCHEMBL5025337 | 0.84 | ABL1 (0.47) | NSD2EHMT2 | |
| SCHEMBL5025339 | 0.84 | ABL1 (0.47) | NSD2EHMT2 | |
| SCHEMBL5025172 | 0.83 | ABCB1 (0.47) | NSD2EHMT2 | |
| SCHEMBL5025175 | 0.83 | ABCB1 (0.47) | NSD2EHMT2 | |
| SCHEMBL20709081 | 0.82 | GPR119 (0.38) | GPR119NSD2EHMT2PDE4APDE4B | |
| SCHEMBL28405729 | 0.82 | GPR119 (0.38) | GPR119NSD2EHMT2PDE4APDE4B | |
| SCHEMBL30727149 | 0.82 | GPR119 (0.38) | GPR119NSD2EHMT2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015079251-A1 | QUINAZOLINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | GPR119 3303/4885NSD2 301/4885SLC2A1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.